Get the Stockscreener App
9.73
5.07%
-0.52
After Hours:
9.71
-0.02
-0.21%
Replimune Group Inc stock is traded at $9.73, with a volume of 2.31M.
It is down -5.07% in the last 24 hours and up +132.22% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$10.25
Open:
$10.24
24h Volume:
2.31M
Relative Volume:
0.38
Market Cap:
$759.48M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-3.0791
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
+10.57%
1M Performance:
+132.22%
6M Performance:
-0.51%
1Y Performance:
-17.26%
1-Day Range:
$9.70
$10.35
1-Week Range:
$9.095
$10.85
52-Week Range:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
9.73 | 800.07M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-20-25 | Upgrade | Wedbush | Neutral → Outperform |
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
How Replimune Group Inc. stock compares to growth peers2025 Performance Recap & Fast Entry High Yield Tips - newser.com
Trend analysis for Replimune Group Inc. this weekTrade Ideas & Daily Stock Momentum Reports - newser.com
What recovery options are there for Replimune Group Inc.Volume Spike & Real-Time Price Movement Reports - newser.com
How to build a custom watchlist for Replimune Group Inc.Insider Selling & Technical Pattern Based Buy Signals - newser.com
Price momentum metrics for Replimune Group Inc. explainedMarket Rally & Consistent Growth Equity Picks - newser.com
Will Replimune Group Inc. stock benefit from AI adoptionWatch List & Trade Opportunity Analysis Reports - newser.com
What to do if you’re stuck in Replimune Group Inc.Market Sentiment Summary & Daily Price Action Insights - newser.com
Why Replimune Group Inc. stock is a must watch in 2025Trade Signal Summary & Daily Profit Maximizing Tips - newser.com
What hedge fund activity signals for Replimune Group Inc. stock2025 Market Sentiment & Weekly Stock Breakout Alerts - newser.com
How to use Fibonacci retracement on Replimune Group Inc.Trade Volume Summary & High Win Rate Trade Alerts - newser.com
What risks investors should watch in Replimune Group Inc. stockJuly 2025 Summary & Low Drawdown Trading Strategies - newser.com
Brokers Set Expectations for Replimune Group Q2 Earnings - MarketBeat
Is Replimune Group Inc. stock a buy before product launchesEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
Replimune Group (NASDAQ:REPL) Stock Price Up 9.2% After Analyst Upgrade - MarketBeat
HC Wainwright Forecasts Replimune Group Q2 Earnings - MarketBeat
Replimune Group (REPL) Price Target Increased by 48.75% to 10.84 - Nasdaq
Traders Buy High Volume of Call Options on Replimune Group (NASDAQ:REPL) - MarketBeat
How Replimune Group Inc. stock reacts to Fed rate cuts2025 Year in Review & Fast Gaining Stock Reports - Fundação Cultural do Pará
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2025-10-27 17:22:37 - newser.com
Opinion | The Spin Doctors at the FDA - The Wall Street Journal
HC Wainwright Upgrades Replimune Group to Buy From Neutral, Price Target is $12 - MarketScreener
H.C. Wainwright upgrades Replimune stock rating to Buy on RP1 approval chances - Investing.com Canada
Replimune Group (NASDAQ:REPL) Upgraded to Buy at HC Wainwright - MarketBeat
HC Wainwright & Co. Upgrades Replimune Group (REPL) - Nasdaq
REPL Receives Analyst Upgrade and New Price Target Today | REPL Stock News - GuruFocus
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):